78 results about "Sustained-Release Preparations" patented technology

The invention relates to the technical field of food sustained-release preparations, and particularly discloses a sour cherry powder sustained-release preparation with a stable uric acid reducing effect and a preparation process of the sour cherry powder sustained-release preparation. The sour cherry powder sustained-release preparation comprises a core active phase freeze-dried sour cherry powder, a sustained-release carrier phase, a synergistic function phase, an auxiliary regulation phase and a filler, the synergistic functional phase contains a celery seed extract, a curcumin-phospholipid complex, a prebiotic complex and the like, and all the components have a synergistic effect. The preparation method comprises the following steps: carrying out wall breaking, enzymolysis, purification and freeze-drying treatment on sour cherry fruits to obtain a core raw material, compounding the core raw material with other components, and carrying out slow-release carrier construction, coating granulation and other steps to prepare the microcapsule structure preparation. The preparation can be used for assisting in reducing the uric acid level, and has the advantages of high stability of active ingredients, continuous and stable uric acid reducing effect, consideration to intestinal health and the like; the preparation process adopts freeze-drying and micro-capsule coating technologies, effectively retains active ingredients, is controllable in operation, and is suitable for large-scale production.

The invention provides a penicillamine sustained-release preparation. The release rate of the penicillamine sustained-release preparation is adjusted through a specific sustained-release coating. Unexpectedly, the release rate can be obviously improved by adding a small amount of lactose. More unexpectedly, in the prescription system provided by the invention, under the condition that the weight gain of the sustained-release coating is the same, the penicillamine sustained-release preparation which can be released for 12 hours or 24 hours can be respectively obtained only by adjusting the content of lactose, that is, the release rate of the penicillamine sustained-release preparation in 12 hours or 24 hours can reach 85% respectively. According to the penicillamine sustained release preparation provided by the invention, the medication compliance can be improved, and the blood concentration fluctuation can be reduced.

The invention belongs to the technical field of medicines, and particularly relates to a donepezil sustained release preparation and a preparation method thereof, the method comprises the following steps: mixing donepezil, a biodegradable polymer, an amphiphilic polymer and a stabilizer, shearing, curing, and freeze-drying to obtain donepezil microsphere freeze-dried powder. The donepezil sustained release preparation can realize controllable and sustained release of donepezil, the microspheres are good in character and high in stability, meanwhile, the preparation method is simple and convenient, and industrial large-scale production is easy to realize.

The invention relates to the technical field of pharmaceutical preparations, in particular to a solid dispersion-based sustained-release drug composite carrier as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out synergistic spray drying on double polymers (hydroxypropyl methylcellulose acetate succinate and polyvinylpyrrolidone-vinyl acetate copolymer) to form a solid dispersion; compounding with mesoporous silica and calcium silicate for localization, and spraying ethanol to activate pores; calcium stearate and magnesium stearate are sequentially added for lubrication; prefabricating a sustained-release skeleton master batch; and finally, mixing, rolling and forming. According to the method, through hierarchical structural design, the drug stability, the powder fluidity and the release controllability are remarkably improved, the method is suitable for industrial production of the dihydroergoline mesylate sustained release preparation, and a release curve is smooth and reliable.

The invention discloses a muscle-bone regeneration sustained-release preparation for targeting knee joint cartilage and a preparation process thereof, the preparation is composed of a cartilage targeting peptide modified PLGA-hyaluronic acid composite nanoparticle sustained-release carrier, an active regeneration component, a biocompatible matrix and an anti-inflammatory component, nanoparticles are prepared by a multiple emulsion solvent evaporation method, and targeting peptide is modified; the composite concentrated growth factors, stem cells and traditional Chinese medicine extracts have the functions of targeted enrichment, long-acting slow release, anti-inflammation and cartilage regeneration promotion, and can be used for knee joint cartilage defect repair.

The invention discloses a beta-alanine sustained release preparation, the sustained release preparation takes beta-alanine as a core material and a non-allergen wall material as an embedding material, and the non-allergen wall material is pea protein and / or ethyl cellulose. The sustained-release preparation disclosed by the invention is appropriate in release rate, not only can effectively relieve side effects generated after taking beta-alanine, but also can meet the health-care function of improving athletic ability in a short time, so that the beta-alanine sustained-release preparation disclosed by the invention can be widely applied to foods and / or health-care products.

The invention provides a smearing sustained-release preparation and a preparation method and application thereof, the smearing sustained-release preparation comprises a chemotherapeutic drug component, an immune drug component and a sustained-release auxiliary material, and the smearing sustained-release preparation is in a transparent flowable sol shape. The sustained release preparation disclosed by the invention can be smeared and applied to a focus part in situ after a tumor operation. The application effect comprises the following steps: filling the treatment window period of the traditional postoperative adjuvant chemotherapy, and improving the local drug concentration of the focus through in-situ local slow release of the drug, thereby effectively removing residual tumor tissues and reducing the systemic toxicity of drug treatment; the metastasis and recurrence rate of tumors are further inhibited through the synergistic combined effect of chemotherapy-immune drugs in the preparation. The advantages show that the smearing sustained-release preparation provided by the invention has huge clinical potential in the aspect of tumor treatment.

The invention provides a drug sustained release preparation for inhibiting vascular intimal hyperplasia and a preparation method and application thereof, and belongs to the technical field of biological medicine and vascular surgery. The drug sustained release preparation for inhibiting vascular intimal hyperplasia comprises a temperature-sensitive high polymer material and an MRTF / SRF pathway inhibitor, the temperature-sensitive high polymer material is a Pluronic type triblock copolymer; and the effective component of the MRTF / SRF pathway inhibitor is CCG222740 or CCG203971. The invention further discloses a preparation method of the MRTF / SRF pathway inhibitor. The drug sustained release preparation for inhibiting the vascular intimal hyperplasia can continuously release the MRTF / SRF pathway inhibitor at a fixed point in the AVF and other vascular injury repair process, can reduce at least 50% of neointimal area and vascular intimal-intimal thickness, and effectively inhibits the intimal hyperplasia.

The invention relates to the technical field of bacteriostatic agents, in particular to a plant perfume compound microorganism sustained release preparation as well as a preparation method and application thereof. The plant perfume compound microorganism sustained release preparation is prepared from the following raw materials in parts by mass: 2 to 4 parts of clove oil, 6 to 10 parts of citronellal, 1 part of an emulsifier, 2 to 4 parts of chitosan, 2 to 10 parts of sodium alginate, 2 to 6 parts of weathered coal humic acid, 2 to 6 parts of a compound bacterium agent, 10 to 20 parts of charcoal, 2 to 6 parts of amino-terminated polyamidoamine and 0.0002 to 0.0008 part of genipin. Through a triple synergistic mechanism of bacteriostasis of the complex microbial inoculant, slow release of plant active ingredients and rhizosphere micro-ecological regulation and control, the bottleneck that a single biotechnology is low in control effect and short in lasting effect is broken through, compared with chemical control, the cost is greatly reduced, and the method is suitable for an organic pineapple planting system and has remarkable economic and ecological benefits.

The application discloses a sustained-release preparation of indobufen and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The application relates to a sustained-release preparation of indobufen and a preparation method and application thereof. The preparation has the characteristics of stable sustained-release effect, high bioavailability, good drug-taking compliance and small side effect, and is suitable for the prevention and / or treatment of diseases such as ischemic cardiovascular diseases, ischemic cerebrovascular diseases and venous thrombosis.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The present application relates to microspheres having a physiologically active substance uniformly dispersed therein and sustained-release preparations containing the same. In the present application, microspheres are provided, which are microspheres having a physiologically active substance uniformly dispersed therein with a lactic acid / glycolic acid copolymer (PLGA) as a main component, characterized in that the average volume-based particle diameter of the microspheres is 1 μm or more and 150 μm or less, and no lump or pore of the physiologically active substance of 1.5 μm or more is present in the microspheres. The microspheres of the present application can appropriately control the initial release amount of the physiologically active substance and the release rate during the period thereafter, and continuously release the physiologically active substance in vivo for a certain period.

The application discloses an exosome sustained-release preparation and application thereof in treatment of tendon injury, and the sustained-release preparation takes a silk fibroin frozen sponge as a carrier, and the carrier is loaded with exosomes. The application provides the silk fibroin frozen sponge as the carrier of the exosomes, and the silk fibroin frozen sponge has good biocompatibility and biodegradability; the sustained release of the exosomes is realized by controlling a protein fiber network structure of the silk fibroin. The application utilizes the silk fibroin frozen sponge to release the exosomes in situ at a tendon injury site, so that a better tendon repair effect is achieved.

The invention relates to the technical field of breeding regulation and control of black goats, in particular to a hormone treatment method for inducing estrus synchronization of black goats, which comprises the following steps: placing a CIDR vaginal suppository containing 1.38-1.56 g of progesterone into the vagina of an ewe, and keeping for 12-14 days; 48 hours before the thrombus is removed, intramuscularly injecting a sustained release preparation of 330 IU follicle-stimulating hormone and 30% polyvinylpyrrolidone; when the thrombus is removed, intramuscularly injecting a mixed solution containing 330IU pregnant mare serum gonadotropin and 0.1 mg of cloprostenol; 24 hours after the thrombus is removed, 25 micrograms of luteinizing hormone is intravenously injected to release hormone A3; single-time artificial insemination is performed within 48-56 hours after injection, 0.5 ml of semen is left for each injection, and the number of effective sperms is not less than 1.5 * 10 < 8 >. By precisely regulating and controlling CIDR progesterone and multi-hormone stepped injection, the estrus synchronization rate of a group is larger than or equal to 95%, and the traditional synchronization bottleneck is broken through; insemination parameters are controlled and optimized management is carried out, each fetal live lamb is 2.5-3.0, and the breeding efficiency is improved; treatment is started 45-50 days after delivery, the lambing interval is 210 + / -10 days, and large-scale efficient breeding is assisted.

The invention provides a tamsulosin hydrochloride sustained release preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: spraying an ethanol water solution of tamsulosin hydrochloride on a mesoporous silica carrier, and drying to obtain a drug-containing carrier; mixing the drug-containing carrier, an auxiliary carrier, an adhesive and water, and carrying out wet granulation to obtain a drug-containing soft material; extruding and rounding the medicine-containing soft material to obtain a medicine-containing pellet core; coating the drug-containing pellet core with a coating solution to obtain a coated pellet core; the coating liquid comprises an enteric-coated material and a plasticizer; and mixing the coated pellet core with a lubricant to obtain the tamsulosin hydrochloride sustained release preparation. The tamsulosin hydrochloride sustained-release preparation prepared by the method is good in drug content stability, stable in main drug release, simple in process, high in controllability and suitable for industrial production.

The invention discloses a cat and dog gastrointestinal inflammation alleviator containing plant extracts and application of the cat and dog gastrointestinal inflammation alleviator, and relates to the field of pet health. The alleviator is prepared by compounding a plant extract component, a micro-ecological component, a functional auxiliary component and a carrier raw material, plant active components are purified by adopting an ultrasonic-assisted ethanol gradient elution combined membrane separation technology, and the problem of antagonism of a plant extract and probiotics is solved through microcapsule embedding and step-by-step compounding. The sustained-release preparation is prepared by combining sustained-release preparation forming and palatability optimization technologies. The traditional Chinese medicine composition can synergistically achieve the effects of resisting inflammation, repairing gastrointestinal mucosa, regulating intestinal flora and quickly stopping diarrhea, is suitable for preventing and treating acute and chronic enterogastritis of cats and dogs, and is good in palatability, high in stability, free of obvious toxic and side effects and convenient to administrate.

The present invention discloses a carrier with a drug sustained-release function and its application. The carrier is used to carry drugs and achieve a drug sustained-release effect. The carrier is in a gel state, a semi-solid state, or a solid state. The main component of the carrier is a fatty acid polyol ester, in which hydrogenated vegetable oil is dissolved. The carrier's morphology is adjusted by adjusting the amount of hydrogenated vegetable oil dissolved. The present invention mainly uses fatty acid polyol ester and hydrogenated vegetable oil to form a carrier, and then adds other drugs or compounds to achieve the purpose of sustained release. The sustained-release carrier can be prepared into an anhydrous gel, a semi-solid, or a solid, and can be used for the cavitary mucosa of animals and humans. The sustained-release carrier of the present invention does not destroy or reduce the efficacy of the active substance of the drug, and its sustained-release process is stable and effective, overcoming the shortcomings of traditional sustained-release preparations.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an arginine ibuprofen biphasic sustained release preparation and a preparation method thereof. Through a two-phase system of quick-release particles and slow-release particles, the problems that a traditional preparation takes effect slowly, is short in medicine effect and poor in taste are solved. Wherein the quick-release granules are prepared by mixing and granulating ibuprofen arginine, a filling agent, an adhesive and a natural flavoring agent, so that the effective blood concentration can be ensured to be reached within 15 minutes after the medicine is orally taken so as to quickly relieve pain, and the bad flavor of the medicine can be synchronously covered; the sustained-release granules are based on an ibuprofen arginine drug-loading core, the outer layer of the sustained-release granules is coated with a sustained-release film formed by a sustained-release agent and a plasticizer, and the effective blood concentration can be stably maintained for 6-8 hours, so that the medicine taking frequency is reduced, the sustained-release granules only need to be taken for 1-2 times every day, the medication compliance of a patient is greatly improved, and the sustained-release granules are suitable for clinical application. The traditional Chinese medicine composition is especially suitable for clinical scenes needing long-term or repeated analgesia such as chronic arthritis and postoperative pain, has excellent safety and practicability, and has a wide market application prospect.

A brivaracetam pharmaceutical composition contains an active pharmaceutical ingredient, a matrix forming agent, and a swelling agent. It has a sustained release effect and has a more flat release curve compared with a common gel skeleton sustained-release preparation, and thus achieves the purposes of reducing the release rate of the medicament, controlling the in vivo effective dosage of the medicament, stabilizing the blood concentration, reducing toxic and side effects and reducing the times of daily administration.

To provide a sustained-release preparation.SOLUTION: The sustained-release preparation contains, based on the total weight of the preparation, an active ingredient comprising an acetone extract of gamboge resin in an amount of 25.00 wt.% to 31.25 wt.%, sodium lauryl sulfate in an amount of 4 wt.% to 25 wt.%, hydroxypropyl methylcellulose in an amount of 15.63 wt.% to 23.44 wt.%, microcrystalline cellulose in an amount of 6.25 wt.% to 13.38 wt.%, silicon dioxide in an amount of 0.63 wt.% to 1.56 wt.%, magnesium stearate in an amount of 0.63 wt.% to 1.56 wt.%, lactose in an amount of 25.00 wt.% to 40.13 wt.%, and dextrose in an amount of 5.00 wt.% to 7.81 wt.%.SELECTED DRAWING: Figure 2

The invention relates to the technical field of biological medicines, in particular to application of biotin medicines and application of a biotin sustained release preparation. Biotin drugs are used for preparing drugs for promoting cartilage formation, retarding osteoarthritis progress and inhibiting cartilage loss, and can effectively relieve and treat osteoarthritis.

The invention discloses a preparation method of a traditional Chinese medicine composition for treating skin tinea, allergic dermatitis and acne, and relates to the field of pharmaceutical preparations, the extraction rate of gallic acid and ethyl gallate contained in total tannin in fructus chebulae flesh, fructus terminaliae billericae flesh and fructus chebulae immaturus is improved through an enzymolysis method, and the transfer rate of effective components of quercetin is improved through a boiling granulation technology; therefore, the effect of treating psoriasis of the composition is improved. By adopting a boiling granulation technology, the technical problems of long preparation period and high cost in the prior art are solved. The release speed of aloe in intestinal tracts is controlled by adopting a slow release technology, and the upper and lower limit content range of barbaloin is controlled to reduce the occurrence rate of adverse reactions of the composition. Meanwhile, butyl hydroxy anisd (BHA), butylated hydroxytoluene (BHT) and a citric acid system are adopted, so that the problems of PEO skeleton degradation, out-of-control drug release behavior and insufficient main drug stability of the barbaloin-PEO sustained release preparation are solved.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a 4-aminopyridine sustained release preparation and a preparation method thereof. The sustained release preparation comprises 4-aminopyridine, ethyl-beta cyclodextrin-calcium carbonate microspheres, a filler, an adhesive, a disintegrating agent and a lubricant. According to the sustained-release preparation, the sustained-release time can be prolonged, the medicine taking frequency is reduced, the content uniformity of the preparation is improved, meanwhile, the preparation process is improved, and stimulation to operators, environment control in a production workshop and equipment cost are reduced.

The invention relates to the technical field of sustained-release preparation, in particular to a microcrystalline sustained-release preparation and a preparation method thereof.The sustained-release preparation comprises a core composed of edaravone rodlike microcrystals and a shell composed of 2-4 double layers, the shell comprises at least one polyethylene glycol-polylysine copolymer inner layer, and the polyethylene glycol-polylysine copolymer inner layer is a polyethylene glycol-polylysine copolymer outer layer. And at least one outer layer of hyaluronic acid modified with a CD44 targeting peptide. The CD44 targeting peptide modified by the shell layer can specifically recognize a CD44 receptor on the surface of an inner ear hair cell, so that the binding efficiency of a preparation, a round window membrane and a target cell is remarkably improved, the diffusion of a drug to non-target tissues is reduced, and the local drug concentration is improved.

The application belongs to the technical field of microbial preparation, and specifically discloses a kind of SA-MPN encapsulated bacteriophage preparation and its preparation method and application, its preparation method includes the following steps: take bacteriophage cocktail concentrate, add tannic acid solution, FeCl3·6H2O solution, phosphate buffer solution, obtain metal phenolic aldehyde network encapsulated bacteriophage;Subsequently, CaCl2 solution and sodium alginate solution are added to the metal phenolic aldehyde network encapsulated bacteriophage in sequence, to obtain sodium alginate-metal phenolic aldehyde network-bacteriophage mixture microcapsules.The application adopts the above-mentioned SA-MPN encapsulated bacteriophage preparation and its preparation method and application, which can effectively protect bacteriophage from gastric acid, high temperature and ultraviolet stress, realize intestinal targeting and slow release, has high encapsulation efficiency, good stability, antioxidant activity, significant antibacterial effect on salmonella and high biological safety.

The invention relates to the technical field of nano drug loading, in particular to a florfenicol derivative long-acting sustained release preparation and a preparation process thereof. The invention discloses a florfenicol-PEG-PLGA (poly (lactic-co-glycolic acid)-polyethylene glycol-poly (lactic-co-glycolic acid))-PLGA (poly (lactic-co-glycolic acid)) copolymer with a specific proportion, magnetic targeting microspheres, an antioxidant compound containing various components, a pH-responsive coating material and enzyme-responsive nanogel, wherein the derivative is formed by connecting florfenicol and 2-mercaptobenzothiazole; all the components are synergistic, so that long-acting slow release, targeting and intelligent drug release are realized, and the stability of the preparation is guaranteed. The method has outstanding advantages; the innovative components have a synergistic effect, can accurately target a diseased region, and intelligently release drugs in different environments; the composition can improve the drug concentration of diseased regions, enhance the curative effect, reduce the dosage and toxic and side effects, reduce the breeding cost, and have wide application prospects.

The invention discloses a pesticide sustained-release preparation and a preparation method thereof, and belongs to the technical field of pesticide sustained-release preparations, water is subjected to ultrasonic treatment, protective gas is introduced, lauryl sodium sulfate is added and dissolved, then two soluble metal salts are added, the pH value is adjusted to 9.5-11.5 for a reaction, the two soluble metal salts are converted into layered double hydroxides, and the layered double hydroxides are subjected to ultrasonic treatment to obtain the pesticide sustained-release preparation. Meanwhile, sodium dodecyl sulfate is intercalated into the layered double hydroxide, and organic layered double hydroxide, namely organic LDHs, is obtained; and dispersing the organic layered double hydroxide in a biopesticide to obtain the pesticide sustained release preparation. The lauryl sodium sulfate is intercalated into the organic LDHs, and a hydrophobic phase is constructed between layers of the organic LDHs, so that the adsorption capacity of hydrophobic pesticide is remarkably increased, the permeability of the organic LDHs is remarkably reduced through intercalation of the lauryl sodium sulfate, and the release rate of biological pesticide is effectively slowed down.

The present invention belongs to the field of drug delivery and food and pharmaceutical technology, and specifically relates to resistant starch for intestinal-targeted sustained-release of polyphenols, and a preparation method and application thereof, comprising the following steps: preparing quinoa polyphenol extract; annealing and recrystallizing heat-dispersed high-amylose maize starch in an ethanol solution to obtain single-helix resistant maize starch; self-assembling single-helix resistant maize starch and quinoa polyphenol extract in an alcohol-water system to obtain intestinal-targeted sustained-release of polyphenol / resistant starch. The intestinal-targeted sustained-release of polyphenol / resistant starch prepared by the method of the present invention has a specific starch helical structure that can realize intestinal-targeted controlled release of polyphenols in the content, reduce the loss of phenolic compounds during gastrointestinal digestion, realize the precise and continuous release of polyphenol compounds in the intestinal digestion stage, and prolong the retention time of polyphenols in the intestine, thereby improving the bioavailability of polyphenols.

The invention relates to the technical field of pharmaceutical preparations, in particular to a goserelin sustained-release microsphere, a goserelin sustained-release microsphere, a preparation method thereof and a sustained-release preparation. The goserelin sustained release microsphere comprises a medicinal active ingredient goserelin and a polymer carrier lactide-glycolide copolymer, wherein the molar ratio of a lactic acid unit to a glycolic acid unit is 75: 25-95: 5. The goserelin sustained release microsphere and the sustained release preparation have the advantages of long drug release period, almost no hysteresis period and sustained and stable release in vivo.